P311 Inhibitors
Chemical inhibitors of P311 can exert their inhibitory effects through various mechanisms by targeting specific signaling pathways and enzymes that are associated with the functional activity of P311. Wortmannin and LY294002 are inhibitors of phosphoinositide 3-kinases (PI3K), a key component of the Akt signaling pathway. The Akt pathway plays a critical role in cell migration and wound healing processes in which P311 is known to be involved. By inhibiting PI3K, these chemicals effectively reduce Akt activation, leading to a functional inhibition of P311's role in these cellular processes. Similarly, Rapamycin targets the mTOR complex, another integral part of the PI3K/Akt pathway, which influences P311 activity. The inhibition of mTOR by Rapamycin results in a downstream reduction of P311's involvement in the related cellular functions.
Additionally, several chemicals act on the MAPK/ERK and JNK pathways, which are also associated with P311's role in cellular dynamics. PD98059 and U0126 are specific inhibitors of MEK, a kinase that is necessary for the activation of the ERK pathway. By inhibiting MEK, these chemicals decrease ERK activation, and consequently, the activity of P311 in promoting cell migration is reduced. SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which can regulate cell migration and repair processes involving P311. SB203580, which inhibits p38 MAPK, targets the stress response functions of P311. Inhibition of this kinase leads to reduced P311 activity in stress-related cellular responses. The Src family kinase inhibitor PP2, the ROCK inhibitor Y-27632, and the EGFR inhibitors Gefitinib and Erlotinib all act on upstream regulators or signaling molecules that influence the pathway cascades in which P311 is active. By inhibiting these regulators, the respective chemicals decrease the activation of pathways that are critical to P311's functions. Lastly, Sorafenib, a multi-kinase inhibitor, targets receptors involved in the MAPK pathway, leading to a direct reduction in the functional processes associated with P311.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent inhibitor of phosphoinositide 3-kinases (PI3K), which are upstream of Akt signaling, a pathway where P311 is implicated in facilitating cell migration and wound healing. Inhibition of PI3K by Wortmannin would reduce Akt activation, leading to a decrease in the cellular processes that P311 is known to enhance. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 specifically inhibits PI3K, which plays a critical role in the Akt pathway, a signaling cascade that is associated with the function of P311. Inhibition of PI3K activity by LY294002 would result in reduced Akt signaling, thereby functionally inhibiting the processes P311 is involved in. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is an inhibitor of mitogen-activated protein kinase kinase (MEK), which is part of the MAPK/ERK pathway. P311 is known to promote ERK pathway activity, which is involved in cell migration. PD98059 would inhibit MEK, thereby reducing ERK activation and subsequently decreasing P311-mediated cellular responses. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which can regulate cell migration and repair processes in which P311 is involved. Inhibition of JNK by SP600125 would lead to impairment of these P311-associated functions. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAPK, a kinase that participates in cell stress responses and is related to the signaling pathways involving P311. By inhibiting p38 MAPK, SB203580 can reduce the functional activity of P311 in cellular stress responses. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits the mammalian target of rapamycin (mTOR), which is a part of the PI3K/Akt pathway, a signaling cascade that P311 is known to facilitate. Inhibition of mTOR by Rapamycin would lead to a downstream reduction in P311-promoted processes. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is an inhibitor of Src family tyrosine kinases, which are upstream regulators of several pathways, including those involving P311. Inhibition of Src by PP2 would decrease the activation of pathways where P311 functions are critical. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK, which in turn is important for the ERK pathway's activation. Since P311 is associated with the ERK pathway, U0126 would inhibit this pathway, leading to a decrease in P311-involved signaling. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 is an inhibitor of the Rho-associated protein kinase (ROCK), which is implicated in cell migration and cytoskeletal organization, processes where P311 is involved. Inhibition of ROCK by Y-27632 can diminish P311-associated cellular functions. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. EGFR signaling can regulate pathways that involve P311. By inhibiting EGFR, Gefitinib would lead to a functional inhibition of P311-dependent signaling pathways. | ||||||